0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IGF-I R

IGF-I R

IGF-I R Molecule Information

Name:Insulin-like growth factor I receptor
Target Synonym:Insulin-like growth factor 1 receptor alpha chain;CD_antigen=CD221;Insulin-like growth factor 1 receptor beta chain;IGF1R;Insulin-like growth factor 1 receptor;Insulin-like growth factor I receptor;IGF-I receptor
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:33
Lastest Research Phase:Approved

IGF-I R Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IGR-H5229 Human Human IGF-I R / CD221 Protein
IGR-H5229-structure
IGR-H5229-sds
IGR-H5229-elisa_1
IGR-C5225 Cynomolgus Cynomolgus IGF-I R / CD221 Protein, His Tag
IGR-C5225-structure
IGR-C5225-sds
IGR-C5225-elisa_1
IGR-R5224 Rat Rat IGF-I R / CD221 Protein, His Tag
IGR-R5224-structure
IGR-R5224-sds
IGR-R5224-elisa_1
IGR-M5223 Mouse Mouse IGF-I R / CD221 Protein, His Tag
IGR-M5223-structure
IGR-M5223-sds
IGR-M5223-elisa_1

IGF-I R Molecule Synonym Name

IGF1R,CD221,IGFR,JTK13,CD221,MGC142170,MGC142172,MGC18216

IGF-I R Molecule Background

The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the ¦Á and ¦Â subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane ¦Á¦Â chain.The ¦Á chains are located extracellularly while the ¦Â subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the ¦Á chains induce the tyrosine autophosphorylation of the ¦Â chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

IGF-I R References

IGF-I R Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Mecasermin (Ipsen) IGF-1; FK-780; MKN-031 Approved Ipsen INCRELEX fda Growth failure IPSEN INC 2005-08-30 Growth failure Details
Brigatinib AP-26113 Approved Ariad, Takeda ALUNBRIG fda Anaplastic lymphoma kinase (ALK)-positive NSCLC, Metastatic non-small cell lung cancer ARIAD 2017-04-28 Anaplastic lymphoma kinase (ALK)-positive NSCLC, Metastatic non-small cell lung cancer Details
Ceritinib LDK-378; NVP-LDK378; NVP-LDK378-NX,LDK378,LDK 378 Approved Novartis ZYKADIA fda Non small cell lung cancer (NSCLC) NOVARTIS 2014-04-29 Non small cell lung cancer (NSCLC) Details
Mecasermin (Astellas/OrphanPacific) Approved Astellas, OrphanPacific Mecasermin 日本 Growth hormone deficit, Dwarfism, Insulin receptor abnormality, Lipoatrophic diabetes OrphanPacific 1994-10-05 00:00:00.0 Dwarfism, Insulin receptor abnormality, Lipoatrophic diabetes, Growth hormone deficit Details
IGF-1 (Biogen/Pharmacia & Upjohn) Approved Biogen, Pharmacia & Upjohn Dwarfism Details
Mecasermin Rinfabate SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3 Approved Insmed IPLEX fda Growth failure INSMED 2005-12-12 Growth failure Details

IGF-I R Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
W-0101 (Pierre Fabre Medicament) W-0101 Phase Ⅱ Pierre Fabre Solid tumours Details
VF-001 VF-001; VF-001-DP-HD; VF-001-DP-LD,VF 001; VF 001 DP HD; VF 001 DP LD,VF001; VF001 DPHD; VF001DPLD Phase Ⅱ Factor Therapeutics Leg ulcer Details
AMT-070 AMT-070 Preclinical Digna Biotech, Amsterdam Molecular Therapeutics Liver cirrhosis Details
Insulin-Like Growth Factor 1 (Wright State Physicians) Phase Ⅰ Wright State Physicians Sunburn, Skin aging Details
Teprotumumab RO-4858696; HZN-001; R-1507; RG-1507 BLA Filing Genmab, Roche, River Vision Development Corp Graves ophthalmopathy Details
Ganitumab AMG-479 Phase Ⅲ Amgen, Millennium Pharmaceutical, National Cancer Institute Solid tumours, Ewing's Sarcoma Details
Cixutumumab A-12; IMC-A12; LY-3012217; NSC-742460 Phase Ⅱ Lilly, National Cancer Institute Breast cancer, Solid tumours, Soft tissue sarcoma, Sarcoma, Hepatocellular carcinoma (HCC), Head and neck cancer, Rhabdomyosarcoma, Thymic tumor, Neuroendocrine tumors (NET), Non small cell lung cancer (NSCLC), Prostate cancer, Esophageal adenocarcinoma, Colorectal cancer, Pancreatic cancer Details
Pegylated insulin-like growth factor 1 RG-7010; IGF1-PEG Phase Ⅰ Roche Amyotrophic lateral sclerosis (ALS) Details
XL-228 XL-228 Phase Ⅰ Exelixis Solid tumours, Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) Details
VPI-2690B VPI-2690B Phase Ⅱ University of North Carolina, Vascular Pharmaceuticals Diabetic nephropathy Details
KW-2450 KW-2450 Phase Ⅱ Kyowa Hakko Kirin Breast cancer Details
PL-2258 PL-2258; PL2258-Merck; PL-2258B Phase Ⅰ Merck Sharp & Dohme, Piramal Phytocare Solid tumours Details
INSM-18 INSM-18; INS-18; TT-100,INSM18 Phase Ⅱ Insmed, University of California Prostate cancer Details
ATL-1101 ATL-1101 Phase Ⅰ Antisense Therapeutics Psoriasis Details
Anti-IGF-1R monoclonal antibody (Genentech) rhuMAb-IGFR Phase Ⅰ Genentech Solid tumours Details
CT-707 CT-707 Phase Ⅱ Centaurus Biopharma Non small cell lung cancer (NSCLC) Details
BMS-754807 BMS-754807,BMS754807 Phase Ⅱ Bristol-Myers Squibb Breast cancer Details
Linsitinib ASP-7487; OSI-906; OSI-906AA,ASP7487,OSI906,OSI906AA Phase Ⅲ Astellas, National Cancer Institute Adrenocortical carcinoma Details
Mecasermin (Chiron/SkyePharma) Phase Ⅱ Chiron, SkyePharma Osteoarthritis (OA) Details
CT102 CT-102 Phase Ⅰ Institute of Pharmacology & Radiation of AMMS, Hangzhou Tianlong Pharmaceuticals Hepatocellular carcinoma (HCC) Details
124I-CPD-1023-figitumumab FPX-1028; CPD-1028-[125I]; CPD-1028-[124I]; 125I-CPD-1028; 124I-CPD-1028 Phase Ⅰ Fusion Pharma Cancer Details
Picropodophyllin AXL-1717; NSC-36407; PPP,AXL1717 Phase Ⅱ Axelar Non small cell lung cancer (NSCLC), Astrocytoma Details
IGV-001 IGV-001 Phase Ⅰ Imvax Glioblastoma Details
AVE-1642 AVE-1642 Phase Ⅱ ImmunoGen, Sanofi Breast cancer, Solid tumours, Multiple myeloma (MM) Details
Figitumumab CP-751871 Phase Ⅲ Pfizer Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Breast cancer, Multiple myeloma (MM), Ewing's Sarcoma, Head and neck cancer, Cancer Details
Rinfabate Phase Ⅰ Insmed Solid tumours Details
Dalotuzumab MK-0646; F-50-035; h7C-10 Phase Ⅱ Pierre Fabre, Merck Sharp & Dohme Breast cancer, Colorectal cancer Details
PL-225B PL-225B,PL225B Phase Ⅰ Piramal Phytocare Solid tumours Details
FPX-01 (Fusion Pharmaceuticals) FPX-01;[225Ac]-FPI-1434 Phase Ⅰ Fusion Pharma Solid tumours Details
Istiratumab MM-141; XLR461MD3M (UNII code) Phase Ⅱ Merrimack, Shire, Adimab Ovarian cancer, Pancreatic cancer Details
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) Phase Ⅰ Sidney Kimmel Cancer Center Glioma Details
BIIB-022 BIIB-022 Phase Ⅰ Biogen Non small cell lung cancer (NSCLC), Solid tumours, Hepatocellular carcinoma (HCC) Details
Robatumumab 19-D12; SCH-717454; SCHOOL-717454,19D12 Phase Ⅱ Merck Sharp & Dohme Solid tumours, Colorectal cancer, Sarcoma, Osteosarcoma Details

This web search service is supported by Google Inc.

totop